QIAGEN Enters Collaboration With Eli Lilly To Support Development Of QIAstat-Dx In-vitro Diagnostic To Detect APOE Genotypes Which Can Play Role In Diagnosis Of Alzheimer's Disease; No Terms Disclosed
Portfolio Pulse from Benzinga Newsdesk
QIAGEN has entered a collaboration with Eli Lilly to develop the QIAstat-Dx in-vitro diagnostic for detecting APOE genotypes, which are significant in Alzheimer's disease diagnosis. This will be the first commercially available IVD for APOE genotyping.
September 04, 2024 | 8:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly collaborates with QIAGEN to support the development of the QIAstat-Dx IVD for APOE genotyping, enhancing their role in Alzheimer's disease diagnostics.
By collaborating with QIAGEN, Eli Lilly strengthens its involvement in Alzheimer's diagnostics, potentially boosting its reputation and influence in the medical field.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
QIAGEN's collaboration with Eli Lilly to develop the QIAstat-Dx IVD for APOE genotyping marks a significant advancement in Alzheimer's diagnostics.
The collaboration with Eli Lilly positions QIAGEN at the forefront of Alzheimer's diagnostics, potentially increasing demand for their products and enhancing their market position.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80